Drugs / V260
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02062385 | May 2014 → Jun 2015 | Rotavirus infection | Merck Sharp & Dohme LLC | Completed | Met primary |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2012-05-25 | Merck Sharp & Dohme LLC | Government of Rwanda Introduces Merck’s ROTATEQ® (Rotavirus Vaccine, Live, Oral, Pentavalent) to Help Protect Children Against Rotavirus merck.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | V260 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02062385 ↗ |
| Known as | RotaTeq | “V260 (RotaTeq™; live, oral, pentavalent rotavirus vaccine)” NCT02062385 ↗ |
| Modality | Vaccine | “live, oral, pentavalent rotavirus vaccine” NCT02062385 ↗ |
| Route | Oral | “V260 administered as a 2 mL oral solution” NCT02062385 ↗ |